Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation

Published: Saturday, August 16, 2014
Last Updated: Saturday, August 16, 2014
Bookmark and Share
Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio.

Miltenyi Biotec has announced that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.

“It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale,” said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. “With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner.”

Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Most Complete Human Brain Model to Date is a ‘Brain Changer’
Once licensed, model likely to accelerate study of Alzheimer’s, autism, more.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Protein That Turns Moles Into Melanoma Cancer Identified
Moles can turn into cancer, if the genetic factors recently identified by a team of researchers at the University of Pennsylvania were not present in humans.
Scientists Grow Human Serotonin Neurons in Petri Dish
The advance could facilitate the discovery of new antidepressants and drugs for illnesses involving serotonin.
Study Details Powerful Molecular Promoter of Colon Cancers
Findings show how suppression of microRNA family of molecules leads to intestinal tumors.
From Pluripotency to Totipotency
Studies results provide new elements for the understanding of pluripotency and could increase the efficiency of reprogramming somatic cells to be used for applications in regenerative medicine.
Cancer Treatment Models get Real
Researchers at Rice Univ. and Univ. of Texas MD Anderson Cancer Center have developed a way to mimic the conditions under which cancer tumors grow in bones.
Potential Treatment for Muscular Dystrophy
A new method for producing muscle cells could offer a better model for studying muscle diseases, such as muscular dystrophy, and for testing potential treatment options.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!